Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Low-dose colchicine (0.5 mg/day) has emerged as an effective anti-inflammatory strategy for secondary prevention in atherosclerotic cardiovascular disease.
By inhibiting microtubule assembly, colchicine suppresses activation of the NLRP3 inflammasome, leading to reduced interleukin-1β and interleukin-6 signaling, key drivers of plaque inflammation and instability.
Clinical trial data demonstrate that colchicine significantly stabilizes atherosclerotic plaques, attenuates neutrophil activation, and reduces thrombogenic potential.
A pooled analysis of randomized trials shows a 25% relative reduction in major adverse cardiovascular events (HR ~0.75), with consistent reductions in myocardial infarction (≈23%), ischemic stroke (≈22%), and cardiovascular mortality (≈34%).
These benefits occur without an increase in non-cardiovascular mortality and with good tolerability in most patients.
Taken together, these findings position colchicine as a third pillar of secondary prevention, complementing lipid-lowering and antithrombotic therapies by targeting residual inflammatory risk in patients with established atherosclerosis.”
Stay updated with Hemostasis Today.
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians
-
Jul 30, 2026, 14:22Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
-
Jul 30, 2026, 14:09Hilal Ahmad: New Guidelines for Pediatric Ischemic Stroke Management